thebench.bio #1 Ecosystem for the Bio-Tech Industry

Regulatory Daily Summary

Regulatory Daily Summary: What Happened on November 14, 2026

EMA committee backs seven medicines and flags Mounjaro contraception concerns

The committee supported 11 indication extensions and a dapivirine vaginal ring that lasts three months.

  • Updated
  • Read from 1 article, 1 publication

Today in brief

The EMA’s drug committee recommended marketing authorization for seven medicines, including treatments for lung cancer and hypertension.1 It also adopted a communication about Mounjaro and oral contraceptive reliability, and supported 11 indication extensions.1

EMA committee recommends seven medicines and flags Mounjaro contraception concerns

At its November meeting, the EMA’s Committee for Medicinal Products for Human Use, or CHMP, recommended marketing authorization for seven medicines.1 The recommendations include Aumseqa for non-small cell lung cancer, Baxfendy for inadequately controlled hypertension, and Zybrivo for non-squamous non-small cell lung cancer in adults.1

The committee also backed two insulin-aspart biosimilars, Garzulys and Donrafylix, for diabetes in people aged one year and older.1 It recommended extending Gazyvaro’s use to adults with active, moderate-to-severe systemic lupus erythematosus not adequately controlled by standard treatment, and Isturisa’s use to children and adolescents aged six and older with endogenous Cushing’s syndrome.1

For Mounjaro, the CHMP adopted a communication about possible effects of tirzepatide on oral contraceptive reliability.1 The communication advises women who could become pregnant to use contraception and says evidence about tirzepatide’s effects on oral contraceptives is limited for women with obesity, overweight, or type 2 diabetes.1 After the European Commission decides, the authorization holder will distribute the communication to health professionals, and it will appear on EMA and national register websites.1

The CHMP recommended indication extensions for 11 medicines, including Gazyvaro and Isturisa.1 It also backed a 100 mg dapivirine vaginal ring for HIV-1 prevention, which can be replaced every three months instead of monthly.1 The ring was assessed through the EU-M4All procedure, with WHO experts and regulators from Kenya, South Africa, and Zambia participating.1

After re-examining two medicines, the committee maintained its recommendations against authorization.1

Also published